You're invited to participate in the

TREMFYA® (guselkumab) NATIONAL BROADCAST

Patient Profiles

NEW DATA AVAILABLE

in Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis

April W. Armstrong, MD, MPH

MODERATOR
Associate Dean, University of Southern California
Vice Chair and Associate Professor of Dermatology
University of Southern California
Keck School of Medicine
Los Angeles, CA

Philip Mease, MD, MACR

Director, Rheumatology Research, Swedish Medical Center/Providence-St. Joseph Health and
Clinical Professor, University of Washington
School of Medicine and
Seattle Rheumatology Associates
Seattle, WA

Sergio Schwartzman, MD

Franchellie M. Cadwell
Associate Professor of Clinical Medicine,
Weill Cornell Medical College
Associate Attending Physician, New York-Presbyterian
Hospital and Hospital for Special Surgery
New York, NY

Bruce E. Strober, MD, PhD

Yale University
New Haven, CT
Central Connecticut Dermatology Research
Cromwell, CT

Watch Live Online *From Anywhere*

TOPICS

Review TREMFYA® clinical efficacy and safety data from the VOYAGE 1 and VOYAGE 2 pivotal trials

Review TREMFYA® clinical efficacy and safety data from the ECLIPSE trial

Review TREMFYA® clinical efficacy and safety data from the DISCOVER 1 and DISCOVER 2 trials

Thursday, September 10, 2020
Broadcast 1: 7:00 PM ET
Broadcast 2: 9:30 PM ET
Meeting Code: 2020-01400

RSVP at www.MyDomeProgramRegistration.com
Please contact your Janssen Biotech, Inc., representative if you have any questions regarding the program.

INDICATIONS

TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

DOSAGE AND ADMINISTRATION

TREMFYA® is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. In active psoriatic arthritis, TREMFYA® may be administered alone or in combination with a cDMARD (e.g., methotrexate).

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections

TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations

Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS

Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

Disclosures

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Janssen Biotech, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

The Speakers received compensation for participation in this program.

Please read our Privacy Policy.

If you have questions or you no longer wish to receive e-mail invitations from me, please let me know.

Tremfya® (guselkumab)

Janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Janssen Biotech, Inc.
800 Ridgeview Drive
Horsham, PA 19044